InvestorsHub Logo
Followers 58
Posts 10088
Boards Moderated 1
Alias Born 09/21/2016

Re: McMagyar post# 118594

Tuesday, 09/05/2017 12:04:48 PM

Tuesday, September 05, 2017 12:04:48 PM

Post# of 459899

ANAVEX™ 2-73 is an orally available, small-molecule activator of the sigma-1 receptor which, data suggest, is pivotal to restoring neural cell homeostasis and promoting neuroplasticity.1  Donepezil is currently the leading compound for the treatment of Alzheimer’s disease in more than 50 countries and is postulated to exert a therapeutic effect by enhancing cholinergic function.  ANAVEX™ 2-73 is to advance this year into a Phase 2/3 clinical trial for the treatment of Alzheimer’s disease, as well as other neurodegenerative and neurodevelopmental CNS indications, including the orphan designation Rett syndrome.

1 Advances in Experimental Medicine and Biology Volume 964 2017 Sigma Receptors: Their Role in Disease and as Therapeutic Targets



Use of the "P" word in this context is nice to see.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AVXL News